MYLUNG Consortium Part 3: Observational Study
NCT05885698
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Carcinoma, Non-Small-Cell Lung
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- US Oncology Research
- Last updated on ClinicalTrials.gov
- May 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Southern Cancer Center, PC · Daphne, AL
Florida · 1
- Cancer Care Centers of Brevard, Inc. · Palm Bay, FL
Illinois · 1
- Affiliated Oncologists, LLC · Chicago Ridge, IL
New York · 1
- New York Oncology Hematology, P.C. · Albany, NY
Ohio · 1
- Oncology Hematology Care Clinical Trials, LLC · Cincinnati, OH
Oregon · 1
- Willamette Valley Cancer Institute and Research Center · Eugene, OR
Virginia · 2
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care · Blacksburg, VA
- Virginia Oncology Associates · Newport News, VA
Washington · 1
- Northwest Cancer Specialists, P.C. · Vancouver, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.